Literature DB >> 12654678

Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest.

María del Carmen Conejo1, Luis Martínez-Martínez, Alvaro Pascual, Ana Isabel Suárez, Evelio J Perea.   

Abstract

The in vitro activities of ABT-773 were evaluated against 15 Listeria monocytogenes strains and 196 coryneform bacteria isolated from clinical samples. One hundred percent of the L. monocytogenes strains were inhibited by </=0.015 micro g of ABT-773/ml. MICs of ABT-773 ( micro g/ml) at which 50% of the isolates tested were inhibited (MIC(50)s) and MIC(90)s for other organisms were 0.125 and 0.5 (Corynebacterium amycolatum), 1 and >32 (Corynebacterium jeikeium), 0.03 and >32 (Corynebacterium minutissimum), >32 and >32 (Corynebacterium pseudodiphtheriticum and Corynebacterium urealyticum), 0.125 and >32 (Corynebacterium striatum), and 0.03 and 0.5 (Rhodococcus equi), respectively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654678      PMCID: PMC152506          DOI: 10.1128/AAC.47.4.1403-1406.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Comparative in vitro activity of ABT-773, a novel antibacterial ketolide.

Authors:  A M Nilius; M H Bui; L Almer; D Hensey-Rudloff; J Beyer; Z Ma; Y S Or; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Antimicrobial susceptibility pattern of Corynebacterium striatum.

Authors:  L Martínez-Martínez; A Pascual; K Bernard; A I Suárez
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  Most Corynebacterium xerosis strains identified in the routine clinical laboratory correspond to Corynebacterium amycolatum.

Authors:  G Funke; P A Lawson; K A Bernard; M D Collins
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

4.  Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and coryneform bacteria isolated from clinical samples.

Authors:  L Martínez-Martínez; P Joyanes; A I Suárez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

5.  In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes.

Authors:  L Martínez-Martínez; A Pascual; A I Suárez; E J Perea
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

Review 6.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

7.  Antimicrobial susceptibility patterns of some recently established coryneform bacteria.

Authors:  G Funke; V Pünter; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Comparison of E-test with broth microdilution and disk diffusion for susceptibility testing of coryneform bacteria.

Authors:  L Martínez-Martínez; M C Ortega; A I Suárez
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

9.  In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria.

Authors:  L Martínez-Martínez; A Pascual; A I Suárez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Phenotypic characteristics of 31 strains of Corynebacterium striatum isolated from clinical samples.

Authors:  L Martínez-Martínez; A I Suárez; J Winstanley; M C Ortega; K Bernard
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

View more
  2 in total

1.  Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 2.  Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust.

Authors:  Els Van de Perre; Gina Reichman; Deborah De Geyter; Caroline Geers; Karl M Wissing; Emmanuel Letavernier
Journal:  Front Med (Lausanne)       Date:  2021-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.